Ann: Safety Review Committee Approves Second Cohort, page-21

Thanks that report doesn't necessarily have it ending in Q4 of CY23, there isn't CY24 on their diagram.

Perhaps it's all to do with patient numbers and how engaged the hospitals are in the trial

Looking at Nono (Nerinetide) and their phase 2 trial it took them 2.5 years.

(Between Sept 16, 2008, and March 30, 2011, we randomly allocated 197 patients to treatment )

The primary outcome was safety and primary clinical outcomes were the number and volume of new ischaemic strokes defined by MRI at 12–95 h after infusion.

Their phase 3 trail was then only published in 2020 with endpoint at day 90.

Analysis of the primary endpoint of the proportion of patients who achieve functional independence after 90 days across all trial participants